VHT vs XLV: Choosing Between Vanguard and State Street for US Healthcare ETF Exposure

The Quick Take

• Vanguard Health Care ETF (VHT) and State Street's XLV are the two dominant US healthcare sector ETFs, together managing hundreds of billions in assets and offering different portfolio construction approaches to the same sector.
• VHT tracks the broader MSCI US Investable Market Health Care Index covering approximately 400 holdings, while XLV tracks the S&P 500 Health Care sector, concentrating exposure in ~65 large-cap names.
• For income investors, XLV's slightly higher dividend yield and liquidity premium make it the tactical choice; for long-term growth investors, VHT's small-cap and mid-cap healthcare exposure adds upside optionality from biotech and medtech innovators.

The comparison between Vanguard Health Care ETF (VHT) and SPDR Health Care ETF (XLV) represents one of the most common portfolio construction decisions for US equity investors seeking defensive sector exposure with healthcare's structural growth characteristics. Both ETFs track US-listed healthcare companies but with meaningfully different index methodologies: VHT's broader index of approximately 400 holdings includes small and mid-cap healthcare innovators in biotech, medtech, and specialized services, while XLV's concentration in ~65 S&P 500 constituents limits exposure to the largest, most liquid healthcare businesses.

From a tactical allocation perspective, the choice between VHT and XLV reflects a bet on different aspects of the healthcare investment cycle. During periods of risk aversion, XLV's large-cap concentration provides tighter bid-ask spreads and lower tracking error, making it the preferred institutional rebalancing vehicle. During periods of healthcare innovation momentum — such as biotech catalyst cycles and FDA approval seasons — VHT's small-cap exposure captures valuation multiples that large-cap incumbents cannot match. Both ETFs benefit from healthcare's defensive revenue characteristics: pharmaceutical and medical device revenues have historically shown low economic cyclicality, making the sector an outperformer during recessions.

Forward signals include the Federal Reserve's interest rate trajectory, which affects healthcare sector valuations through two channels: lower rates expand the DCF value of high-growth biotech companies (benefiting VHT's broader index more than XLV), while a steeper yield curve signals economic expansion that historically sees healthcare underperform cyclical sectors. Investors should monitor the Medicare and Medicaid reimbursement rate announcements from CMS, which directly affect revenue for hospitals, insurers, and pharmaceutical distributors — the largest XLV holdings. The macro variable is US presidential healthcare policy: any major regulatory shift in drug pricing, insurance mandates, or Medicare negotiation scope would restructure earnings across both ETFs' largest holdings.

Synthesized from 1 source.